Subscribe
shutterstock_2131359385_sruilk
9 November 2023BiotechnologyMarisa Woutersen

Taiwan company fails to overturn PTAB decision over eye treatment patent

Federal Circuit rejects appeal in patent dispute with California’s Cloudbreak Theraputics | Court stated failure to prove concrete injury.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Novartis sues Regeneron over eye treatment
22 March 2018   Novartis has accused competitor Regeneron of patent infringement through the latter’s sale of Eylea and Zaltrap.
Big Pharma
Novartis to boost eye care portfolio with $3.4bn buy
10 May 2019   Novartis is set to acquire assets associated with Xiidra ((lifitegrast ophthalmic solution), a dry eye treatment, from Takeda.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Americas
Novartis sues Regeneron over eye treatment
22 March 2018   Novartis has accused competitor Regeneron of patent infringement through the latter’s sale of Eylea and Zaltrap.
Big Pharma
Novartis to boost eye care portfolio with $3.4bn buy
10 May 2019   Novartis is set to acquire assets associated with Xiidra ((lifitegrast ophthalmic solution), a dry eye treatment, from Takeda.

More on this story

Americas
Novartis sues Regeneron over eye treatment
22 March 2018   Novartis has accused competitor Regeneron of patent infringement through the latter’s sale of Eylea and Zaltrap.
Big Pharma
Novartis to boost eye care portfolio with $3.4bn buy
10 May 2019   Novartis is set to acquire assets associated with Xiidra ((lifitegrast ophthalmic solution), a dry eye treatment, from Takeda.

More features

Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York
UPC deals further blow to Dexcom in glucose monitor dispute with Abbott
‘A marathon and a sprint at the same time’: How we won $452m damages